# Inflazome

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inflazome

- Industry: Pharmaceuticals
- Headquarters: Dublin, Ireland
- Website: www.inflazome.com
- Total disclosed funding: $62M
- Latest round: Series B (Nov 19, 2018)
- Investors on record: 4

## About

Inflazome Ltd. is a biotechnology company specializing in the development of innovative therapies targeting inflammatory diseases, aiming to improve patient outcomes through precision medicine.Founded in 2016 and headquartered in Dublin, Ireland, Inflazome Ltd. focuses on creating breakthrough treatments for inflammatory conditions. The company has successfully completed a TRADE SALE in September 2020, where it was acquired by F. Hoffmann-La Roche Ltd for EUR 380 million, with potential milestone payments. The total amount raised by the company stands at EUR 380 million from 4 deals, highlighting its traction in the biotechnology sector. The founder's details are not provided.Inflazome Ltd. specializes in therapeutic solutions that address inflammatory diseases, leveraging advanced scientific research to develop novel compounds. Their product pipeline includes innovative treatments that are designed to modulate immune responses, with a focus on conditions such as cardiovascular diseases, neurodegenerative disorders, and metabolic syndromes. The company’s solutions are directed towards healthcare professionals and institutions in key markets including Europe and North America, driving advancements in patient care.In the most recent year of 2019, Inflazome Ltd. reported a revenue of EUR 0 and an EBITDA of EUR -28,148,830.1, reflecting the early-stage nature of its operations as it moves towards monetizing its innovative therapeutic offerings.Inflazome Ltd. aims to leverage its recent acquisition by F. Hoffmann-La Roche Ltd to expedite the development and commercialization of its therapeutic products. The focus is on expanding its product portfolio with new treatments for inflammatory diseases, although specific upcoming product launches have not been disclosed. The company also plans to enhance its presence in North America and Europe, utilizing the EUR 380 million received from the TRADE SALE to support research and development initiatives and to strengthen its market position.

## Funding rounds

- Series B, Nov 19, 2018, $45M — Novartis Venture Fund, Forbion, Longitude Capital, Fountain Healthcare Partners
- Series A, Sep 11, 2016, $17M — Novartis Venture Fund, Fountain Healthcare Partners

## Investors

- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A, Series B
- Fountain Healthcare Partners (https://capitalatlas.ai/funds/fountain-healthcare-partners) — Series A, Series B
- Forbion (https://capitalatlas.ai/funds/forbion) — Series B
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series B